A Peptide Fragment Called MR-proADM Shows Promise for Diagnosing and Predicting Sepsis Outcomes | Research

The takeaway

A review of 22 studies found that mid-regional pro-adrenomedullin (MR-proADM) is a reliable biomarker for diagnosing sepsis and predicting mortality, especially when tracked over time.

AUC >0.8
for mortality prediction in sepsis, indicating strong prognostic accuracy across multiple studies

What the researchers found

Across 22 studies reviewed, MR-proADM demonstrated strong utility as a biomarker for both diagnosing sepsis and predicting outcomes in septic shock patients. Its prognostic accuracy improved during patient follow-up, with area under the curve (AUC) values exceeding 0.8 for mortality prediction in several studies.

The biomarker's performance was enhanced when combined with other biomarkers or clinical severity scores, and it showed particularly strong correlation with the degree of organ failure. MR-proADM also showed potential value in specific subpopulations, including sepsis patients with burns or malignant tumors.

Why it matters

Sepsis kills millions worldwide each year, and early detection remains one of the biggest challenges in critical care medicine. Finding a reliable blood-based biomarker that can both diagnose sepsis early and predict who is most likely to deteriorate could save lives by enabling faster, more targeted treatment. MR-proADM — a stable fragment of the peptide adrenomedullin — appears to fill this role better than many existing biomarkers.

How the study worked

The authors conducted a narrative review by searching PubMed, Web of Science, and The Cochrane Library for studies on MR-proADM in sepsis. They included 22 studies, one opinion paper, and one review paper. No exclusion criteria for age, sex, ICU admission, or comorbidities were applied. The review examined both diagnostic and prognostic performance across general sepsis populations and specific subgroups.

What this study cannot tell us

This is a narrative review, not a systematic review or meta-analysis, so it lacks rigorous quality assessment of included studies. No randomized controlled trials were available. The included studies varied in design, patient populations, and measurement methods. The authors acknowledge that larger prospective studies and RCTs are still needed to confirm these findings.

How to read the evidence

This is a narrative review synthesizing 22 observational studies. While it provides a useful overview, it lacks the methodological rigor of a systematic review or meta-analysis and included no randomized controlled trials.

When this study was published

Published in 2018, this review covers literature available at that time. MR-proADM research has continued since, with the biomarker gaining wider clinical adoption in Europe, making this still relevant as foundational context.

The bigger picture

The search for reliable sepsis biomarkers has been ongoing for decades. Procalcitonin and C-reactive protein are widely used but imperfect. MR-proADM represents a peptide-based approach that may outperform these conventional markers, particularly for prognosis and monitoring disease progression. As precision medicine advances, combining MR-proADM with other biomarkers and clinical scores could create more accurate risk stratification tools for critically ill patients.

Questions still open

How does MR-proADM perform compared to procalcitonin and other established sepsis biomarkers in head-to-head trials?
What is the optimal MR-proADM threshold value for clinical decision-making in sepsis?
Could serial MR-proADM monitoring guide antibiotic de-escalation in sepsis patients?

Common questions

What is MR-proADM and why is it useful for sepsis?

MR-proADM is a stable fragment of the peptide adrenomedullin, which the body produces in response to infection and organ stress. Unlike adrenomedullin itself, which breaks down quickly in blood, MR-proADM is stable enough to measure reliably. Higher levels indicate more severe sepsis and greater risk of organ failure and death.

Is MR-proADM better than other sepsis biomarkers like procalcitonin?

The review suggests MR-proADM performs well for both diagnosis and prognosis, particularly for predicting mortality and organ failure. It appears to complement existing biomarkers rather than replace them — combining MR-proADM with other markers or clinical scores improved overall accuracy.

Read the original research

Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review.

Healthcare (Basel, Switzerland), 6(3)

View on PubMed ↗Publisher’s paper ↗

Citation

Önal, Uğur; Valenzuela-Sánchez, Francisco; Vandana, Kalwaje Eshwara; Rello, Jordi. (2018). Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review.. Healthcare (Basel, Switzerland), 6(3). https://doi.org/10.3390/healthcare6030110